About MaaT Pharma
MaaT Pharma is a company based in Lyon (France) founded in 2014. MaaT Pharma has raised $42.3 million across 14 funding rounds from investors including Bpifrance, European Union and Symbiosis. MaaT Pharma offers products and services including MaaT013, MET-N, MET-C, gutPrint®, and MaaT033. MaaT Pharma operates in a competitive market with competitors including BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others.
- Headquarter Lyon, France
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Maat Pharma
-
Annual Revenue
$3.35 M (USD)44.34as on Dec 31, 2024
-
Net Profit
-$30.02 M (USD)-46.59as on Dec 31, 2024
-
EBITDA
-$31.76 M (USD)-28.76as on Dec 31, 2024
-
Total Equity Funding
$42.3 M (USD)
in 14 rounds
-
Latest Funding Round
$2.24 M (USD), Grant
Jul 20, 2021
-
Investors
Bpifrance
& 10 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of MaaT Pharma
MaaT Pharma is a publicly listed company on the EURONEXT with ticker symbol MAAT in France, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of MaaT Pharma
MaaT Pharma offers a comprehensive portfolio of products and services, including MaaT013, MET-N, MET-C, gutPrint®, and MaaT033.
Phase 3 therapy for improving cancer patient survival rates.
Microbiome ecosystem treatment for oncology applications.
Gut-focused therapy for cancer-related immune modulation.
Platform for analyzing microbiome in cancer contexts.
Phase 2b treatment for patients undergoing allo-HSCT.
Funding Insights of MaaT Pharma
MaaT Pharma has successfully raised a total of $42.3M across 14 strategic funding rounds. The most recent funding activity was a Grant round of $2.24 million completed in July 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in MaaT Pharma
MaaT Pharma has secured backing from 11 investors, including institutional and venture fund investors. Prominent investors backing the company include Bpifrance, European Union and Symbiosis.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital investments are directed toward life science sectors.
|
Locked | Locked | Locked | |
|
Tech & Life Sciences focused stage agnostic VC firm investing in Europe, Asia & the US
|
Locked | Locked | Locked | |
|
Growth and acquisition investments are managed by Credit Mutuel Equity.
|
Locked | Locked | Locked |
Investor details for MaaT Pharma
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by MaaT Pharma
Investment portfolio details for MaaT Pharma
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - MaaT Pharma
Detailed financials for MaaT Pharma
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Maat Pharma Comparisons
Peer comparison for MaaT Pharma
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of MaaT Pharma
MaaT Pharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| Locked | Locked | Locked |
RNA interference-based therapeutics are developed for multiple disorders.
|
|
| Locked | Locked | Locked |
A biopharmaceutical company accelerating innovative mental health treatments.
|
|
| Locked | Locked | Locked |
An AI-enabled platform is developed for infectious disease treatment.
|
|
| Locked | Locked | Locked |
Biosolutions and enzymes are developed for biotechnology applications across industries.
|
Detailed competitors of MaaT Pharma
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Maat Pharma
Complete news archive for MaaT Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about MaaT Pharma
MaaT Pharma was founded in 2014.
MaaT Pharma is headquartered in Lyon, France. It is registered at Lyon, Auvergne-rhone-alpes, France.
MaaT Pharma is a funded company, having raised a total of $42.3M across 14 funding rounds to date.
Annual revenue of MaaT Pharma is $3.35M as on Dec 31, 2024.
MaaT Pharma was established in 2014 in Lyon, France, within the biotech sector. Microbiome-based treatments are created for addressing intestinal dysbiosis in patients with malignant blood diseases or bone infections. Autologous intestinal microbiota transplants are employed as the primary method. Heavy therapies that induce dysbiosis are countered through these interventions. Operations center on therapeutic development for such conditions, with a focus on clinical applications.
MaaT Pharma's top competitors include Spark Therapeutics, BridgeBio and Forge Biologics.
MaaT Pharma offers MaaT013, MET-N, MET-C, gutPrint®, and MaaT033.
Yes, MaaT Pharma is publicly traded on EURONEXT under the ticker symbol MAAT.
MaaT Pharma has 11 investors. Key investors include Bpifrance, European Union, Symbiosis, Celeste Management, and Skyviews Life Science.
The ticker symbol of MaaT Pharma is MAAT on EURONEXT.